

Caring for Pediatric Patients with Malignant Bone Tumors:

The Advanced Practice Nurse's Perspective

Elizabeth Cummings MSN RN CPNP-AC CPHON

Kristen Dalton MSN RN CPNP-AC CPHON

Amy Rapino MSN RN CPNP-PC

APHON National Conference - September 2020



Disclosures

- No relevant conflicts of interest or disclosures to discuss!



Objectives

- To describe the presentation, diagnosis, and management of pediatric malignant bone tumors
- To explore conference identified learning gaps
- To address how to support patients through the acute and late effects of these tumors and their therapy
- To discuss the APP role and the importance of interprofessional practice in the care of these patients

Case Study #1


- 18 year old male
- 2 month hx of left calf stiffness and weakness
- Symptoms progressed to sharp shooting pain in the back of his left thigh, buttocks, and radiating to the calf
- No urinary or bowel incontinence, saddle anesthesia, fever, decrease in appetite
- 5 pound weight loss over the past 1-2 months

Case Study #1

- Seen in outpatient ortho clinic
- Physical examination
 - 4/5 strength in left leg
 - Hyporeflexia on left leg
 - Decreased sensation over Left thigh
 - Normal rectal tone
 - Limp
 - Unable to plantar flex left foot or do left leg calf raises
- MRI lumbar spine revealed lesion in S2
- Referral to pediatric oncology

Diagnostic Work Up

- MRI lumbar spine
- Biopsy
- CT chest
- PET scan



Diagnostic Work Up: Biopsy


- Needle
- Open incisional
- Lab testing



<https://www.chop.edu/pediatric-fellowships/interventional-radiology/fellowship>

Ewing Sarcoma

- Epidemiology
- Biology
- Genetics
- Risk factors
- Clinical presentation
- Staging
- Prognostic factors



<http://europepmc.org/article/PMC/5808087>

Supportive Care at Diagnosis

- Pain control
- Physical therapy
- Education
- Interprofessional support



https://www.freepik.com/premium-photo/pills-shape-heart-yellow-background-flat-lay-top-view_4902662.htm

Plan

- Diagnostic and staging workup
- Baseline evaluations
- Central line placement
- Chemotherapy
- Re-staging scans
- Local control
- Monitoring after therapy



Chemotherapy

- Neoadjuvant and adjuvant therapy
- Importance of interval compression
- Standard of care
 - VDC
 - IE
- Notable toxicities r/t chemotherapy
- Supportive care during chemotherapy



Surgery

- S2 vertebral tumor - challenging location
- Risks
 - Loss of bladder or bowel function
 - Loss of sensation to foot or ankle
 - Loss of motor function to foot or ankle
 - Tumor recurrence or positive margins

IN DEPTH: Radiation for Ewing Sarcoma

- Radiosensitive tumor
- Efficacy
 - Tumor size and location may influence outcome
 - No randomized controlled trials comparing radiation and surgery
- Generally used when surgery is not an option or if poor functional outcome is expected with surgery

Radiation: Dose

- Measured in Gy
 - Absorption of one joule of radiation per kilogram of matter
 - 1 Gy = 100 cGy
- Definitive Dose for Ewing Sarcoma: 55.8 Gy (5580 cGy)
 - Pre-chemo volume to 45 Gy (4500 cGy)
 - Boost to residual tumor (determined by re-staging scans)
- Dose is divided into daily fractions



Radiation: Planning Process

- CT-Simulation
 - Non-contrast scan
 - Create immobilization devices and place tattoos to replicate position
 - Anesthesia may be required for young children
- SIM CT is fused with diagnostic imaging
- Radiation Oncologist contours the target volumes
- Dosimetrists and Physicists design the beam angles
- Radiation Oncologist reviews and approves the plan (or sends back for revisions)
- Rigorous quality assurance process



Initial Radiation Plan



- Pre-chemo volume to 4500 cGy



Proton Plan

Boost Volume



- Residual tumor volume to 5580 cGy



Proton Plan

Complete Radiation Plan


- Plan Sum



Proton Plan

Radiation Treatment

- Goals
 - #1: Treat the tumor
 - #2: Minimize toxicity to normal cells
- Consider the real estate
 - Bladder
 - Bowel (large and small)
 - Cauda
 - Rectum
 - Femoral heads
- Determine the optimal modality




Radiation Modalities


- **Photons (x-rays)**
 - AP/PA (2D)
 - Most basic, used in the emergent setting
 - 3D
 - Basic - extremities, whole abdomen, whole brain
 - Intensity Modulated Radiation Therapy (IMRT)
 - Superconformal
- **Protons**
 - Double scatter
 - Less conformal, increased dose to skin
 - Pencil Beam Scanning
 - Dose paint, conformal, less dose to normal tissue

Plan Comparison of Radiation Modalities

- Photons vs. Protons




IMRT Plan



Proton Plan

Dose Volume Histogram

- Dose to bladder, bowel, and rectum very low
- Cauda- mean dose is 46 Gy
- Highest dose to tumor



Show DVH	Structure	Approval Status	Plan	Course	Volume [cm ³]	Dose Cover. [%]	Sampling Cover. [%]	Min Dose [cGy]	Max Dose [cGy]	Mean Dose [cGy]
<input checked="" type="checkbox"/>	RECTUM_RT0G	Approved	Plan Sum	C1 PELVIS	143.6	100.0	100.0	0.0	2222.1	45.7
<input checked="" type="checkbox"/>	PTV_5580	Approved	Plan Sum	C1 PELVIS	274.4	100.0	100.0	4830.0	5881.6	5663.9
<input checked="" type="checkbox"/>	PBSTV_5580	Approved	Plan Sum	C1 PELVIS	288.4	100.0	100.0	4829.6	5881.6	5656.8
<input checked="" type="checkbox"/>	Genitalia	Approved	Plan Sum	C1 PELVIS	264.0	100.0	100.0	0.0	0.0	0.0
<input checked="" type="checkbox"/>	FemoralgHead_R	Approved	Plan Sum	C1 PELVIS	171.1	100.0	100.0	0.0	0.0	0.0
<input checked="" type="checkbox"/>	FemoralHead_L	Approved	Plan Sum	C1 PELVIS	165.3	100.0	100.0	0.0	4.5	0.3
<input checked="" type="checkbox"/>	CTV_5580	Approved	Plan Sum	C1 PELVIS	175.0	100.0	100.0	5364.3	5878.2	5681.2
<input checked="" type="checkbox"/>	CTV_4500	Approved	Plan Sum	C1 PELVIS	250.8	100.0	100.0	4778.5	5881.6	5631.6
<input checked="" type="checkbox"/>	CAUDA	Approved	Plan Sum	C1 PELVIS	29.0	100.0	100.1	10.6	5669.6	4607.4
<input checked="" type="checkbox"/>	Bowel_Small	Approved	Plan Sum	C1 PELVIS	545.9	100.0	100.0	0.0	5422.5	132.8
<input checked="" type="checkbox"/>	Bowel_Large	Approved	Plan Sum	C1 PELVIS	394.3	100.0	100.0	0.0	5428.6	286.9
<input checked="" type="checkbox"/>	Bladder	Approved	Plan Sum	C1 PELVIS	208.5	100.0	100.0	0.0	56.1	2.5
<input checked="" type="checkbox"/>	PTV_4500	Approved	Plan Sum	C1 PELVIS	384.9	100.0	100.0	4311.8	5881.6	5564.0

Acute Side Effects of Pelvic Radiation

- Fatigue
- Skin erythema (radiation dermatitis)
- Nausea and vomiting
- Diarrhea
- Anemia, thrombocytopenia
- Delayed count recovery



Late Side Effects of Pelvic Radiation

- Decreased velocity of bone growth
- Arthritis in hip joint (if in the field, usually avoided)
- Slightly increased risk of bowel obstruction, altered bowel habits
- Increased risk of fracture
- Risk of second malignancy

Case Study #2

- 15 year old female
- Presented to orthopedic clinic with 4 weeks hx of right shoulder pain
- Pain when doing push ups during color guard practice
- Pain worsened over several months
- PCP ordered x-rays → referred to local orthopedist
- MRI right shoulder → concern for tumor


Case Study #2

- On exam
 - Firm and fixed mass palpable at right proximal humerus
 - Pain with shoulder abduction + internal/external rotation
 - Tenderness to palpation
 - Neurovascular exam intact
 - No deficits in strength






Diagnostic Work Up

- MRI right shoulder
- IR guided biopsy
- CT chest
- PET scan




Diagnostic Work Up: Imaging



Osteosarcoma

- Epidemiology
- Biology and genetics
- Risk factors
- Predisposition syndromes
- Clinical presentation
- Staging
- Prognostic factors



http://medcell.med.yale.edu/histology/bone_lab/osteosarcoma.php


Supportive Care at Diagnosis

- Pain control
- Occupational vs physical therapy
- Weight bearing precautions
- Education
- Interprofessional support




Plan

- Diagnostic + metastatic workup
- Baseline evaluations
- Central line placement
- Chemotherapy
- Surgery
- Monitoring after therapy



Chemotherapy

- Neoadjuvant and adjuvant therapy
- Standard of care = MAP
 - Methotrexate
 - Doxorubicin
 - Cisplatin
- Local control
- Notable toxicities
- Supportive care



https://link.springer.com/chapter/10.1007/978-1-4419-0284-9_18

Role of Radiation in Osteosarcoma

- NOT a radiosensitive tumor
 - Requires high doses (7000-8000 cGy)
 - Limited by the normal structures in the field
- Considered if no surgical option
- Palliation

IN DEPTH: Surgery

- Local control surgery = wide resection
- Goals
 - Negative margins
 - Maintain function
- Pre-op MRI




Surgery: Limb Salvage


Radical Resection

- Physeal-sparing
- Joint-sparing
- Limb-sparing

Huvos Classification	
Grade	Necrosis
I	Little or no effect, <60% tumor necrosis
II	Areas of viable tumor, 60-89% necrosis
III	Scattered foci, 90-99% tumor necrosis
IV	No histological evidence of viable tumor – 100%




Local Control Surgery: Amputation



Limb Salvage: Vascularized Fibular Reconstruction

- Fibula = appendix
- Microsurgery
- Plate & screws
- Long term considerations




Limb Salvage: Endoprosthetic Reconstruction

- Joint replacement
- Static vs Growing
- Recovery to walk
- Metal and plastic < bone
- Activity level



Local Control Surgery: Van Nes Rotationplasty

- “Almost” Limb Salvage, “Functional Amputation”
- Full activities
- Often will be one and done
- For distal femur/proximal tibial tumors



Case Study #2: Surgery

- Limb salvage
 - Endoprosthetic reconstruction
 - 100% tumor necrosis, negative margins
- OT for shoulder rehabilitation
- Is now >3 years post-surgery
- Doing well!



Local Control Surgery: Postoperative Management

- Wound healing- 2-3 weeks post-op before resuming chemo
- Monitor @ 2 weeks, 6 weeks, 3 months; then every 3-4 months x 3 years, every 6 months year 4 & 5
- Possible complications
 - Infection
 - Non-union
 - Fracture
 - Limb length discrepancy

Local Control Surgery: Take Home Points

- Not “one size fits all” approach
- Primary goal = wide resection
- Chemo is a double edged sword
- Kids are resilient!



Role of the Nurse Practitioner

- Education
 - Patient and family
 - Nursing
 - Medical team
- Advocacy
- Clinical management, monitoring, and supportive care
- Research

Future Directions

- Standard of care
- Phase 2 clinical trials
- Future breakthroughs
 - Chemotherapy
 - Immunotherapy
 - Personalized medicine
 - Imaging
 - Radiation
 - Surgical techniques



<https://nfc.org/blog/sarcoma-awareness-month>

Questions?

References

- Ahmed, S. K., Randall, R. L., DuBois, S. G., Harmsen, W. S., Krailo, M., Marcus, K. J., Janeway, K. A., Geller, D. S., Sorger, J. I., Womer, R. B., Granowetter, L., Greir, H. E., Gorlick, R. G. & Laack, N. N. I. (2017). Identification of patients with localized ewing sarcoma at higher risk for local failure: A report from the Children's Oncology Group. *International Journal of Radiation Oncology Biology Physics*, 99(5), 1286-1294.
- Balamuth, N. J. & Womer, R. B. (2010). Ewing sarcoma. *Lancet Oncology*, 11, 184-192.
- Bishop, M. W., Janeway, K. A. & Gorlick, R. (2016). Future directions in the treatment of osteosarcoma. *Current Opinion in Pediatrics*, 28(1), 26–33.
- Diffenderfer, E. S., Verginadis, I. I., Kim, M. M., Shoniyozov, K., Velalopoulou, A., Goia, D., Putt, M., Hagan, S., Avery, S., Teo, K., Zou, W., Lin, A., Swisher-McClure, S., Koch, C., Kennedy, A. R., Minn, A., Maity, A., Busch, T. M., Dong, L., Koumenis, C., Metz, J. & Cengel, K. A. (2020). Design, implementation, and in vivo validation of a novel proton FLASH radiation therapy system. *International Journal of Radiation Oncology Biology Physics*, 106(2), 440-448.
- DuBois, S. G., Krailo, M. D., Gebhart, M. C., Donaldson, S. S., Marcus, K. J., Dormans, J., Shamberger, R. C., Sailer, S., Nichols, R. W., Healey, J. H., Tarbell, J. A., Lor Randall, R., Devidas, M., Meyers, J. S., Granowetter, L., Womer, R. B., Bernstein, M., Marina, N. & Grier, H. E. (2015). Comparative evaluation of local control strategies in localized ewing sarcoma of bone: A report from the Children's Oncology Group. *Cancer*, 121, 467-475.
- Gaspar, N., Hawkins, D. S., Dirksen, U., Lewis, I. J., Ferrari, S., Le Deley, M., Kovar, H., Grimer, R., Whelan, J., Claude, L., Delattre, O., Paulussen, M., Picci, P., Sunby Hall, K., Van den berg, H., Ladenstein, R., Michon, J., Hjorth, L.,... Oberlin, O. (2015). Ewing sarcoma: Current management and future approaches through collaboration. *Journal of Clinical Oncology*, 33(27), 3036-3046.
- Gorlick, R., Janeway, K. & Marina, N. (2016). Osteosarcoma. In P. A. Pizzo & D. G. Poplack. (Eds.), *Principles and practice of pediatric oncology*. (7th eds). (pp. 877-898). Philadelphia, PA: Wolters Kluwer
- Grohar, P. J., Janeway, K. A., Mase, L. D. & Schmittman, J. D. (2017). Advances in treatment of pediatric bone sarcomas. *American Society of Clinical Oncology Education Book*, 37, 25–735
- Hamilton, S. N., Carlson, R., Hasan, H., Rassekh, S. R. & Goddard, K. (2017). Long-term outcomes and complications in pediatric ewing sarcoma. *American Journal of Clinical Oncology*. 40(4), 423-428.
- Hawkins, D. S., Brennan, B. M. D., Bolling, T., Davidson, D. J., Dirksen, U., DuBois, S. G., Hogendoorn, P. C. W. & Lessnick, S. L. (2016). Ewing sarcoma. In P. A. Pizzo & D. G. Poplack. (Eds.), *Principles and practice of pediatric oncology*. (7th eds). (pp. 855-876). Philadelphia, PA: Wolters Kluwer

References

- Houdek, M. T., Wagner, E. R., Stans, A. A., Shin, A. Y., Bishop, A. T., Sim, F. H. & Moran, S. L. (2015). What is the outcome of allograft and intramedullary free fibula (Capanna technique) in pediatric and adolescent patients with bone tumors? *Clinical Orthopaedics and Related Research*, 474, 660-668.
- Futani, H., Minamizaki, T., Nishimoto, Y., Abe, S., Yabe, H. & Ueda, T. (2006). Long-term follow-up after limb salvage in skeletally immature children with a primary malignant tumor of the distal end of the femur. *The Journal of Bone and Joint Surgery*, 88(3), 595-603.
- LaRiviere, M. J., Santos, P. M. G., Hill-Kayser, C. E. & Metz, J. M. (2019). Proton therapy. *Hematology Oncology Clinics of North America*, 33(6), 989-1009.
- Luetke, A., Meyers, P. A., Lewis, I. & Juergens, H. (2014). Osteosarcoma treatment – where do we stand? A state of the art review. *Cancer Treatment Reviews*, 40, 523–532
- Morris, C. D., Teot, L. A., Bernstein, M. L., Marina, N., Krailo, M. D., Villaluna, D., Janeway, K. A., Dubois, S. G., Gorlick, R. G. & Randall, R. L. (2016). Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children's Oncology Group. *Journal of Surgical Oncology*, 113, 351-354.
- Uezono H, Indelicato D. J., Rotondo, R. L., Mailhot Vega, R. B., Bradfield, S. M., Morris, C. G. & Bradley, J. A. (2020). Treatment outcomes after Proton therapy for ewing sarcoma of the pelvis. *International Journal of Radiation Oncology Biology Physics*, 107(5), 974-981.
- U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. (2017). *Ewing sarcoma treatment*. Retrieved from <https://www.cancer.gov/types/bone/hp/ewing-treatment-pdq>
- U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. (2017). *Osteosarcoma and malignant fibrous histiocytoma of bone treatment*. Retrieved from <https://www.cancer.gov/types/bone/hp/osteosarcoma-treatment-pdq>
- Womer, R. B., West, D. C., Krailo, M. D., Dickman, P. S., Pawel, B. R., Grier, H. E., Marcus, K., Sailer, S., Healey, J. H., Dormans, J. P. & Weiss, A. R. (2012). Randomized controlled trial of interval-compressed chemotherapy in the treatment of localized Ewing sarcoma: A report from the Children's Oncology Group. *Journal of Clinical Oncology*, 30(33), 4148-4154.